NCT00689806

Evaluation of Lovastatin in Severe Persistent Asthma

• Status: Withdrawn
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of Chicago · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study has two purposes: 1. to determine whether lovastatin, a commonly used medication to lower cholesterol in the blood, can produce beneficial changes in airway inflammation and in the airway smooth muscle 2. to examine whether lovastatin will have favorable changes in asthma symptoms of patients with moderate or severe asthma.

Conditions

• Severe Persistent Asthma

Interventions

Type	Name	Description
DRUG	Lovastatin	Lovastatin 20 mg extended release (or placebo) by mouth once daily for weeks 1-4. Liver function test will be checked at week 4 follow up visit. If LFTs are not \> 3 times the upper limit of normal, then the subject will have the dose of extended release lovastatin increased to 60 mg once a day for weeks 4-12
DRUG	Placebo	Placebo by mouth once daily for weeks 1-4.

Timeline

• First posted: 2008-06-04
• Last updated: 2013-06-21